- Home
- PDO vs MNKD Comparison
PDO vs MNKD Comparison
Compare PDO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDO | MNKD |
|---|---|---|
| Founded | 2020 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | PDO | MNKD |
|---|---|---|
| Price | $13.99 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.08 |
| AVG Volume (30 Days) | 695.3K | ★ 4.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | ★ 350.00 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $285,504,000.00 |
| Revenue This Year | N/A | $21.29 |
| Revenue Next Year | N/A | $25.53 |
| P/E Ratio | ★ N/A | $49.71 |
| Revenue Growth | N/A | ★ 43.50 |
| 52 Week Low | $12.65 | $3.29 |
| 52 Week High | $14.25 | $6.51 |
Technical Indicators
Market Signals| Indicator | PDO | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 18.11 |
| Support Level | $13.98 | N/A |
| Resistance Level | $14.06 | $6.08 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 14.00 | 10.27 |
Price Performance
Historical ComparisonAbout PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.